Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
LSTA | US
0.03
1.02%
Healthcare
Biotechnology
30/06/2024
18/10/2024
2.97
2.99
3.00
2.93
Lisata Therapeutics Inc. a clinical-stage pharmaceutical company focuses on the discovery development and commercialization of innovative therapies for the treatment of solid tumors and other diseases. Its product candidates include LSTA1 which is in Phase 1b/2a and 2b clinical studies for the treatment of solid tumor including metastatic pancreatic ductal adenocarcinoma (mPDAC) in combination with a range of anti-cancer regimens; HONEDRA a recipient of SAKIGAKE designation critical limb ischemia; XOWNA that is in Phase IIb clinical trial for the treatment of coronary microvascular dysfunction; and LSTA201 a CD34+ cell therapy for the treatment of chronic kidney disease. The company was formerly known as NeoStem Inc. and changed its name to Caladrius Biosciences Inc. in June 2015. The company was formerly known as Caladrius Biosciences Inc. and changed its name to Lisata Therapeutics Inc. on September 15 2022. Lisata Therapeutics Inc. was incorporated in 1980 and is headquartered in Basking Ridge New Jersey.
View LessStrength based on increasing price with high volume
Low Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Value Stock (Price to Book < 3)
Price Below SMA10D
Microcap (<300M USD)
High Market Beta (> 0.8)
Bearish: Increased Volatility (6-month > 1-month volatility)
10 days
25.6%1 month
41.1%3 months
56.1%6 months
58.3%-
-
0.65
0.01
0.01
0.82
-
-
-23.93M
24.71M
24.71M
-
-
-
-
-44.03
0.92
0.18
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
Range10D
0.35
Range1M
0.43
Range3M
0.91
Rel. volume
1.14
Price X volume
41.81K
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Iterum Therapeutics plc | ITRM | Biotechnology | 1.17 | 26.56M | 7.34% | n/a | -198.11% |
NRXBF | NRXBF | Biotechnology | 0.387 | 26.12M | -0.77% | n/a | 0.00% |
PLUR | PLUR | Biotechnology | 4.75 | 25.98M | -1.22% | n/a | 30845.83% |
Klotho Neurosciences Inc. | KLTO | Biotechnology | 0.7574 | 25.75M | 28.37% | n/a | 0.00% |
Common Stock | NRBO | Biotechnology | 3.03 | 25.72M | -4.11% | n/a | 0.90% |
CytoMed Therapeutics Limited Ordinary Shares | GDTC | Biotechnology | 2.22 | 25.62M | 4.22% | n/a | 3.98% |
Tonix Pharmaceuticals Holding Corp | TNXP | Biotechnology | 0.18 | 25.20M | 0.33% | n/a | 21.99% |
iBio Inc | IBIO | Biotechnology | 2.87 | 24.79M | 0.70% | n/a | 20.92% |
PolyPid Ltd | PYPD | Biotechnology | 3.59 | 24.71M | 4.66% | n/a | 689.01% |
RenovoRx Inc. Common Stock | RNXT | Biotechnology | 1 | 23.99M | 0.00% | n/a | 0.00% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Beasley Broadcast Group Inc | BBGI | Broadcasting - Radio | 12.9 | 19.65M | 2.38% | n/a | 204.46% |
ILAG | ILAG | Building Products & Equipment | 1.03 | 18.60M | 5.10% | n/a | 5.48% |
Antelope Enterprise Holdings Limited | AEHL | Building Products & Equipment | 0.538 | 7.80M | -6.65% | 0.03 | 16.03% |
Forza X1 Inc | FRZA | Recreational Vehicles | 0.2201 | 3.95M | 4.26% | n/a | 0.97% |
EZGO Technologies Ltd. Ordinary Shares | EZGO | Recreational Vehicles | 1.06 | 2.76M | 1.92% | n/a | 17.32% |
Micromobility.com Inc. | MCOM | Recreational Vehicles | 0.01 | 897.66K | -12.28% | n/a | -37.05% |
Winnebago Industries Inc | WGO | Recreational Vehicles | 60.38 | 0 | 0.37% | 22.53 | 56.33% |
Vision Marine Technologies Inc | VMAR | Recreational Vehicles | 3.92 | 0 | -8.84% | n/a | 0.00% |
Twin Vee PowerCats Co. Common Stock | VEEE | Recreational Vehicles | 0.4801 | 0 | -10.26% | n/a | 19.98% |
Urban One Inc | UONEK | Broadcasting - Radio | 1.045 | 0 | -2.34% | n/a | 268.43% |
Parameter | Company | Industry | Indicator |
---|---|---|---|
Enterprise to EBITDA | 0.82 | 0.53 | Expensive |
Ent. to Revenue | - | 3,967.00 | - |
PE Ratio | - | 41.03 | - |
Price to Book | 0.65 | 15.55 | Cheaper |
Dividend Yield | - | 2.20 | - |
Std. Deviation (3M) | 56.11 | 72.80 | Lower Risk |
Debt to Equity | 0.01 | -1.23 | Expensive |
Debt to Assets | 0.01 | 0.25 | Cheaper |
Market Cap | 24.71M | 3.66B | Emerging |